8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
Apr 27, 2026·SEC
XOMA Corporation(XOMAP)Earnings, Financials & Key Ratios
XOMAP•NASDAQ
$24.97
17.1× P/E·Price updated Jul 7, 2026
AboutXOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Show more
- Revenue$52M+83.1%
- EBITDA$14M+136.1%
- Net Income$32M+329.4%
- EPS (Diluted)1.46+188.5%
- Gross Margin94.32%-5.0%
- EBITDA Margin27.53%+119.7%
- Operating Margin21.83%+115.6%
- Net Margin60.81%+225.3%
- ROE34.12%+310.6%
XOMAP Price & Volume
XOMA Corporation (XOMAP) stock price & volume — 10-year historical chart
Loading chart...
Royalty Model Volatility Masks Structural Margin Efficiency
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Clinical Milestone Revenue Dependency
Key Thesis Takeaways
- XOMA's transition to a royalty-aggregator model offers high-margin potential, yet the firm remains heavily exposed to the binary outcomes of clinical-stage assets.
- While the company maintains a robust liquidity buffer with a current ratio of 3.59, the erratic nature of milestone-driven revenue and high fixed SG&A costs of $11.9M in 2026Q1 create significant earnings instability.
- Investors should monitor the sustainability of these royalty streams against the backdrop of a $1.2B retained earnings deficit and the inherent risks of clinical attrition within the portfolio.
Verdict Logic
while the firm maintains a healthy $94.5M cash position, the current P/FCF multiple of 107.10 suggests that the market is pricing in significant future growth that may be derailed by the binary risks of its clinical-stage royalty portfolio.
XOMAP Growth Metrics
XOMA Corporation (XOMAP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.61%
5 Years12.16%
3 Years105.3%
TTM-36.12%
Profit CAGR
10 Years-
5 Years18.98%
3 Years-
TTM1282.58%
EPS CAGR
10 Years-
5 Years13.36%
3 Years-
TTM468.97%
Return on Capital
10 Years-22.21%
5 Years-7.44%
3 Years-12.74%
Last Year5.24%
XOMAP Recent Earnings
XOMA Corporation (XOMAP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (83%)●Beat Revenue 4/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.17+30.5%
$0.13
Rev
$14M+0.3%
$14M
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.26+327.0%
$0.11
Rev
$14M+24.5%
$11M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.78+2050.0%
$0.04
Rev
$9M-18.5%
$11M
Q3 2025
Aug 15, 2025Metric
Actual
Est
EPS
$0.61+508.7%
$0.15
Rev
$13M+19.4%
$11M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.17vs $0.13+30.5% | $14Mvs $14M+0.3% |
| Q2 2026 | Mar 18, 2026 | $0.26vs $0.11+327.0% | $14Mvs $11M+24.5% |
| Q4 2025 | Nov 12, 2025 | $0.78vs $0.04+2050.0% | $9Mvs $11M-18.5% |
| Q3 2025 | Aug 15, 2025 | $0.61vs $0.15+508.7% | $13Mvs $11M+19.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for XOMA Corporation (XOMAP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.97 | $301.22M | 17.10 | 83.06% | 60.81% | 34.12% | 1.22% | |
| $4.38 | $303.37M | -1.39 | 105.77% | -344.95% | -35.74% | — | |
| $17.42 | $42.04M | -0.38 | -3.5% | -624.59% | -16.12% | — | |
| $5.67 | $1.97B | -9.45 | 698.96% | -102.06% | -44.1% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — |
Compare XOMAP vs Peers
XOMA Corporation (XOMAP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XOMAP SEC Filings & Documents
XOMA Corporation (XOMAP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XOMAP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XOMAP Frequently Asked Questions
XOMA Corporation (XOMAP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is XOMA Corporation's revenue?
XOMA Corporation (XOMAP) reported $27.4M in revenue for fiscal year 2025. This represents a 661% increase from $3.6M in 1996.
How fast is XOMA Corporation growing?
XOMA Corporation (XOMAP) grew revenue by 83.1% over the past year. This is strong growth.
Is XOMAP profitable?
Yes, XOMA Corporation (XOMAP) is profitable, generating $33.8M in net income for fiscal year 2025 (60.8% net margin).
Dividend & Returns
Does XOMAP pay dividends?
Yes, XOMA Corporation (XOMAP) pays a dividend with a yield of 1.22%. This makes it attractive for income-focused investors.
What is XOMAP's return on equity?
XOMA Corporation (XOMAP) has a return on equity (ROE) of 34.1%. This is excellent, indicating efficient use of shareholder capital.
What is XOMA Corporation's free cash flow?
XOMA Corporation (XOMAP) generated $6.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.